Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China with over 480 portfolio companies.

She currently sits on the board of Zai Lab, CanSino Biologics, Venus MedTech, dMed, Chain Medical Labs, Berry Oncology, Belief BioMed, ZhenGe, Valgen among others. Her other investments include Gan & Lee, New Horizon Health, Aeonmed Medical, Berry Genomics, Broncus, CITIC Pharma, Crown Bioscience, Kira Pharmaceutical, LIH, Novast Pharmaceuticals, Nurotron, Origene Technologies, Richen, Wuxi Leiming, MedX, Cure Genetics, Goodwill, SinoCell Tech, Sino Biological, Apollomics, Sino United, Schrödinger, Shouti, Jacobio, Hope Medicine, Insilico Medicine, Alamar among others.

Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019, 2020, 2021 and 2022 and named Best Women VCs List by Forbes China.